Drugs News and Research

RSS

Study uncovers transcription control mechanism that is regulated by cancer-causing gene

A comprehensive new gene expression study in embryonic stem cells has uncovered a transcription control mechanism that is not only more pervasive than once thought but is also heavily regulated by the cancer-causing gene c-Myc.

30 Apr 2010

FDA critics say controversy about diabetes drug points to need for agency changes

Reuters: "The controversy surrounding a GlaxoSmithKline Plc diabetes drug points to a need for changes in the way the U.S. Food and Drug Administration handles safety issues, agency critics told lawmakers on Wednesday.

30 Apr 2010

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

American pharmaceutical manufacturers Ortho-McNeil Pharmaceutical LLC and Ortho-McNeil-Janssen Pharmaceuticals Inc., both subsidiaries of Johnson & Johnson, have agreed to pay more than $81 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Topamax, the Justice Department announced today.

30 Apr 2010

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China today reported that its innovative asthma drug Laevo-Bambuterol has received approval from China's State Food & Drug Administration's (SFDA) to commence clinical trials (No.2010L01309 and 2010L01399).

30 Apr 2010

IPS examines how Uganda's anti-counterfeit bill could impact access to generic drugs

Inter Press Service examines Uganda's "controversial Counterfeit Goods Bill," which some say will limit the public's access to "life-saving generic medicines."

30 Apr 2010

Immunogen reports a net loss of $12.1 million in third quarter 2010

ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced financial results for the three-month period ended March 31, 2010 - the third quarter of the Company's 2010 fiscal year (3QFY10).

30 Apr 2010

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Multiple sclerosis (MS) is an equal opportunity destroyer. It attacks the central nervous system and eventually renders most patients disabled. Among its high-profile victims are celebrated cellist Jacqueline du Pre, whose career was ended by MS, and Joan Didion, one of America's greatest writers - but they are far from alone.

30 Apr 2010

Gonorrhea may soon become untreatable according to WHO

According to the World Health organization (WHO), gonorrhea may soon become untreatable and urgent measures need to be taken to prevent and treat the sexually transmitted infection. This is the result of improper use of first line antibiotics which has led to widespread anti microbial resistance to drugs. The cheaper antibiotics no longer have as much effect as they should and the higher antibiotics will soon lose efficacy as well.

30 Apr 2010

Health insurers adopt reform changes early; WellPoint reports rising profits

Following announcements by leading health insurers that their firms would end the practice of rescission, or stripping the sick from their roles, the broader insurance industry followed suit, according to a letter from America's Health Insurance Plans to congressional Democrats, Politico reports. "The decision to end rescission … was made during a Tuesday afternoon conference call of chief executives organized by their trade group, America's Health Insurance Plans, and represents the industry's latest attempt to build political good will after the bruising health care fight."

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten offering of 6,460,672 shares of its common stock at a price of $4.35 per share. After the underwriting discount and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $26.2 million. All of the shares are being sold by Idenix.

29 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Non-Surgical Orthopaedics: Shoulder and upper extremity injuries are very common

Shoulder and upper extremity injuries are very common according to Non-Surgical Orthopaedics, P.C. Many of them result from years of cumulative injuries punctuated by a trauma such as a motor vehicle accident, falls, or sports injuries. These injuries cost consumers, their employers and insurance companies billions of dollars a year in treatment and productivity losses.

29 Apr 2010

Eliminating inherent drug resistance in tuberculosis

Tuberculosis (TB) continues to be a global health problem, in part due to the exceptional drug resistance displayed by the TB-causing agent, Mycobacterium tuberculosis. Beyond even acquired drug resistance, these bacteria are also inherently resistant to many other common antibiotics, which limits the available options in finding alternative treatments to resistant TB strains.

29 Apr 2010

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

Researchers from the University of Minnesota College of Pharmacy have provided the first evidence-based data on changes in drug metabolism in obese children as compared to healthy weight children.

29 Apr 2010

New MDC tool provides alternative choices to user's current prescription drugs

Healthcare reform legislation has enacted changes that will significantly affect the Medicare Part D prescription drug program. The most immediate impact of the reform aims to close the "donut hole", a component of the benefit design in which seniors must pay the full cost for their drugs themselves.

29 Apr 2010

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced that results from a pre-clinical study showed significant improvement in the delivery and half life of Å6, a proprietary peptide treatment for ovarian cancer currently in Phase 2 development by Angstrom Pharmaceuticals. Specifically, the incorporation of NexACT® enabled the dose of Å6 to be cut by half, or from twice per day to once per day delivered subcutaneously, while achieving the same level of efficacy in the mouse lung metastasis model.

29 Apr 2010

Genetic test to predict newborns requiring hospital readmission shortly after birth

The results of two separate research studies taking place at Children's Mercy Hospitals and Clinics will help physicians use genetic testing to prevent complications, and ease the worry of new parents by predicting in advance which newborns may require readmission to the hospital shortly after birth. The studies also will help physicians identify which of their young patients are likely to respond well - or not - to steroid therapy for asthma.

29 Apr 2010

Drugs News and Research

Study uncovers transcription control mechanism that is regulated by cancer-causing gene

FDA critics say controversy about diabetes drug points to need for agency changes

Johnson & Johnson subsidiaries agree to pay over $81M to resolve Topamax illegal promotion allegations

Lotus Pharmaceuticals receives Chinese SFDA approval to commence Laevo-Bambuterol clinical trials

IPS examines how Uganda's anti-counterfeit bill could impact access to generic drugs

Immunogen reports a net loss of $12.1 million in third quarter 2010

Tel Aviv scientist uncovers a new way of detecting multiple sclerosis

Gonorrhea may soon become untreatable according to WHO

Health insurers adopt reform changes early; WellPoint reports rising profits

Canadian researchers identify new therapeutic target for lung cancer

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Idenix Pharmaceuticals prices underwritten offering of common stock at $4.35 per share

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Non-Surgical Orthopaedics: Shoulder and upper extremity injuries are very common

Eliminating inherent drug resistance in tuberculosis

Obese children metabolize caffeine and dextromethorphan at different rates than healthy weight children

New MDC tool provides alternative choices to user's current prescription drugs

Incorporation of NexACT technology helps reduce dose of Å6 compound for ovarian cancer treatment

Genetic test to predict newborns requiring hospital readmission shortly after birth

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News